Skip to Main Content
Try STAT+ TODAY
Trending:
Health
First Opinion
Biotech
Coronavirus
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

GSK buys cancer biotech Tesaro for $5.1B

  • Adam Feuerstein

By Adam Feuerstein Dec. 3, 2018

Reprints
Ovarian Tumor
A section of ovarian tumor. Virginia Commonwealth University Libraries

The Tesaro takeout rumors turned out to be true.

The cancer-focused biotech is being acquired by pharma giant GlaxoSmithKline for $5.1 billion, the companies announced Monday. The deal values Tesaro at $75 per share, or a 63 percent premium to Friday’s closing price.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

I was laid off from a public health job.…
I was laid off from a public health job. Trust me, tech layoffs are different
Medicare Advantage insurers will score $2 billion gift thanks…
Medicare Advantage insurers will score $2 billion gift thanks to limited audits
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Listen: Pharma blockbusters, pandemic policy, & legal chicanery
Listen: Pharma blockbusters, pandemic policy, & legal chicanery
KKR veteran sets records with $3.9 billion health care…
KKR veteran sets records with $3.9 billion health care fund
Unlocking the promise of learning from everyone with cancer
Unlocking the promise of learning from everyone with cancer

Recommended Stories